Valneva Scotland was honored to be invited to attend the Scottish Parliament to present and take questions at the most recent Cross-Party Group meeting on Life Sciences. Managing Director, Greig Rooney, attended the event in Edinburgh alongside four members of the Scottish Parliament and other invited guests from industry and academia. These quarterly sessions focus on key topics in Scotland’s life sciences sector, and our invitation was prompted by our recent award wins and developments at our manufacturing centre of excellence in Livingston, Scotland.
Valneva
Recherche en biotechnologie
Saint-Herblain, Pays de la Loire 38 652 abonnés
Specialty vaccine company focused on prevention of infectious diseases with major unmet need, such as Lyme & chikungunya
À propos
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines, including the world’s first and only chikungunya vaccine, as well as certain third-party vaccines. Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the U.S. with approximately 700 employees.
- Site web
-
http://www.valneva.com
Lien externe pour Valneva
- Secteur
- Recherche en biotechnologie
- Taille de l’entreprise
- 501-1 000 employés
- Siège social
- Saint-Herblain, Pays de la Loire
- Type
- Société cotée en bourse
- Fondée en
- 2013
- Domaines
- vaccines
Lieux
Employés chez Valneva
Nouvelles
-
As global temperatures continue to rise, so does the emerging threat of mosquito-borne diseases. With mosquitos now thriving in more regions, diseases like Chikungunya, Dengue, and West Nile virus are becoming widespread. Whether you are traveling to Europe, Asia, or the Americas, understanding how to help protect yourself is important. Read our latest blog by Dr. Juan Carlos Jaramillo, our Chief Medical Officer, to learn more about the growing risk of mosquito-borne diseases and essential tips for prevention and preparation. https://rb.gy/4zm1or #MosquitoBorneDiseases #infectiousdisease #climatechange #publichealth #AdvancingVaccinesForBetterLives
-
📍 We're in Seoul, South Korea, at the International Society of Vaccines Annual Congress! Valneva is represented by VP Clinical Development Susanne Eder-Lingelbach who is presenting on the two-year antibody persistence and safety data of our single-dose chikungunya vaccine. Details here: https://ow.ly/vYRR50TRktb #InfectiousDiseases #MosquitoBorneDiseases #AdvancingVaccinesForBetterLives
-
📢 In Case You Missed It! On October 10th, Valneva held its Investor Day in New York City, where CEO Thomas Lingelbach, CFO Peter Bühler, and other members of the senior leadership team laid out the Company’s key value drivers for the next 12-18 months and beyond. Key highlights included: Valneva's substantial progress on its Lyme disease vaccine candidate, led by partner Pfizer, further updates on the Company’s promising R&D pipeline and exciting growth opportunities in its commercial vaccine business. The webcast is now available for replay: https://ow.ly/3fjX50TPL7w #AdvancingVaccinesForBetterLives #InvestorDay
-
Valneva to Present on Chikungunya at Several Leading Scientific Conferences https://ow.ly/n0SN50TPSH8
-
We’re proud to announce that the Journal of Travel Medicine has published a pooled safety evaluation for Valneva’s new single-shot live-attenuated chikungunya vaccine. Read more here: https://ow.ly/TiNj50TPBpO
-
Up next in our #EmployeeSpotlight series – meet Michael! As a Quality Control Laboratory Technician, Michael is responsible for delivering precise and reliable data – a high-stress, yet vital, task in ensuring our vaccines meet the required standards throughout their life cycle. Our lab technicians form part of the backbone of our mission to advance vaccines for infectious diseases with significant unmet medical need. Check out our interview with Michael to learn more about his role here at Valneva. #AdvancingVaccinesForBetterLives
-
Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V https://ow.ly/bgcz50TMMxK
-
This International Infection Prevention Week we’re highlighting the vital role of Infection Preventionists (IPs) in “Moving the Needle” on infection prevention. IPs are the unsung heroes working to keep the public healthy and safe, particularly from healthcare-associated infections and many other infectious threats. They develop, implement, and monitor protocols to prevent infections in healthcare settings, and educate both staff and patients about effective prevention practices. Many IPs also help advocate for vaccination, an effective tool to combat the spread of infectious diseases and prevent further outbreaks. Join us this week in honoring the tireless efforts of IPs to keep our communities safe! #IIPW #infectionprevention #vaccines #publichealth #MovingTheNeedle #AdvancingVaccinesForBetterLives
-
Valneva Hosts Investor Day in New York City today at 10 am ET / 4pm CET To register for the live event and webcast click here: https://ow.ly/rU2Q50TIuUS https://lnkd.in/dPbcKEsg
Pages similaires
Parcourir les offres d’emploi
Financement
Dernier round
Capital après introduction en Bourse67 833 293,00 $US